J&J Medical Connect
ERLEADA®

(apalutamide)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

ERLEADA - Posterior Reversible Encephalopathy Syndrome (PRES)

Last Updated: 11/17/2026

SUMMARY  

  • ERLEADA (apalutamide) is an androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR. ERLEADA inhibits AR nuclear translocation, inhibits DNA binding, and impedes AR-mediated transcription.1-3
  • No cases of PRES in patients treated with ERLEADA have been described in the published clinical studies.
  • A retrospective real-world study in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) described the incidence of central nervous system (CNS)-related clinical outcomes (including posterior reversible encephalopathy syndrome [PRES]) among patients with nmCRPC treated with ERLEADA, darolutamide, or enzalutamide.4

CLINICAL DATA

  • No prospective, randomized, clinical trials reporting the incidence of PRES among patients treated with ERLEADA have been published.

Additional data

Retrospective Real-World Study in Patients with nmCRPC

Lledo et al (2025)4 conducted a retrospective real-world, descriptive analysis to describe newly diagnosed CNS-related outcomes, including PRES, among US-based patients with nmCRPC treated with ERLEADA (n=253), darolutamide (n=544), or enzalutamide (n=645). Concomitant use of androgen deprivation therapy was not required for inclusion. The mean duration of the on-treatment observation period was 12.4 months in the ERLEADA group. The proportion of patients who experienced new onset CNS-related conditions in the ERLEADA cohort at 12 months and 24 months post-index were 25.7% and 46.6%, respectively. PRES was not included in the reported CNS-related condition results. The median time-to-new onset of any CNS-related conditions was 29.2 months in the ERLEADA cohort.

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) conducted on 23 October 2026.

References

1 Reviriego C. ARN-509. Androgen receptor signaling inhibitor, prostate cancer therapy. Drugs Future. 2015;40(2):101-108.  
2 Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494-1503.  
3 Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013;31(28):3525-3530.  
4 Lledo DS, Patel C, Joshi K, et al. Real-world assessment of new-onset central nervous system conditions in patients with non-metastatic castration resistant prostate cancer treated with apalutamide, darolutamide, or enzalutamide. Poster presented at: Society of Urologic Oncology (SUO) Annual Meeting; December 2-5, 2025; Phoenix, AZ.  

Would you like to clear and leave your conversation? Message history will be lost.